stockrow
Monday 9 November 2026
Export IMRX’s income statement to Excel — free account
Immuneering Corporation
IMRXImmuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00.
- EPS
- +1.61%
- Free cash flow
- −40.2%
Quarter to September 2026, against a year earlier
3.68
0.31
+9.20%
Follow IMRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 2 | 2 | 0 | — | — | — | 0 | (45.1%) | — | — | 22 | — | |
| Gross margin, % | — | — | — | 35.67 | 44.61 | 44.56 | 50.09 | — | — | — | 0.00 | +14.4 pt | ||||||
| EBT | — | — | — | (8) | (17) | (34) | (51) | (53) | (61) | (56) | (67) | +39.2% | ||||||
| EBT margin, % | — | — | — | (401.59) | (737.18) | (1,627.08) | (15,934.89) | 0.00 | 0.00 | 0.00 | 0.00 | +401.6 pt | ||||||
| Net income | — | 0 | — | (8) | (17) | (34) | (51) | (53) | (61) | (56) | (67) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.08 | 0.47 | 0.15 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.30) | (3.44) | (2.46) | (1.91) | (1.88) | (2.04) | (1.27) | (1.03) | +27.2% | ||||||
| Cash flow | — | — | — | (0.18) | (2.95) | (2.27) | (1.67) | (1.72) | (1.83) | (1.03) | (0.95) | +34.2% | ||||||
| Capex | — | — | — | 0.00 | (0.01) | 0.00 | (0.03) | (0.01) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.18) | (2.96) | (2.27) | (1.70) | (1.74) | (1.84) | (1.03) | (0.96) | +34.3% | ||||||
| Book value | — | — | — | (0.26) | (4.54) | 11.46 | 4.16 | 3.19 | 1.38 | 4.96 | 2.61 | n/m | ||||||
| Shares, m | — | — | — | 26 | 5 | 14 | 26 | 28 | 30 | 44 | 60 | +9.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 33.89 | 33.89 | 105.83 | 333.79 | — | — | — | 751.21 | 126.9 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 1.41 | 0.96 | — | — | — | 1.41 | 0.6 | ||||||
| EV/Sales | — | — | — | 14.35 | 14.35 | 34.10 | 0.91 | — | — | — | 292.52 | 15.9 | ||||||
| EV/FCF | — | — | — | (1.71) | (1.71) | (2.29) | (0.01) | — | — | — | (1.50) | (1.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (15) | (31) | (44) | (49) | (55) | (45) | (62) | +47.0% | |||||
| Capex | — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 | +38.1% | ||||||
| Free cash flow | — | — | — | (4) | (15) | (31) | (45) | (49) | (55) | (45) | (62) | +47.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 14 | 35 | 147 | 101 | 81 | 32 | 166 | 140 | +51.8% | |||||
| Net debt | — | — | — | 3 | (37) | (149) | (106) | (86) | (36) | (173) | (145) | n/m | ||||||
| Shareholders’ equity | — | — | — | (7) | (22) | 156 | 110 | 91 | 41 | 218 | 169 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (109.20) | (64.86) | (32.70) | (34.95) | (47.54) | (78.61) | (39.36) | (31.40) | +69.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (312.34) | (747.69) | (743.47) | (763.99) | (81.29) | (198.38) | (81.3) pt | ||||||
| ROE | — | — | — | 53.15 | 117.48 | (50.24) | (38.00) | (53.36) | (92.51) | (43.12) | (33.53) | (96.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 32 | 64 | 73 | 68 | 66 | 53 | — | +10.6% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Dec 2022 · fundamentals updated 6 Nov 2026
Immuneering Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio, Inc. | $280.4M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | |
| VNDA Vanda Pharmaceuticals Inc. | $231.0M | — (loss-making) | — (loss-making) | +24.10% (above 0%: growing) | n/m | +9.57% (above 0%: growing) | 94.05% | (33.69%) | Compare |
| ACIU AC Immune | $227.0M | — (loss-making) | — (loss-making) | +152.31% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (302.13%) | Compare |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $222.7M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $202.5M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $199.8M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| Median of peers | $225.0M | — | — | +16.64% | — | +9.27% | 97.03% | (76.83%) |
Pay and ownership Proxy statement filed 20 April 2026
Ownership
Directors and executive officers, together
14.90%
Entities affiliated with FMR LLC
13.60%
Benjamin J. Zeskind, Ph.D.
6.80%
HBM Healthcare Investments (Cayman) Ltd.
5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement